Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Véronique del Marmol
Professor Véronique del Marmol is the Head of the Department of Dermatology at Hôspital Erasme, Université Libre de Bruxelles, Belgium. Professor del Marmol graduated as a bachelor in philosophy in 1983 and as an MD in 1987 at the Université de Louvain, Belgium. She graduated as an MSc in molecular biology in 1991 and received her PhD in 1995 for her work on “Contribution to the study of the regulation of human melanogenesis”. She graduated as a specialist in dermato-venerology in 1996 at the Université Libre de Bruxelles.
Skin cancer, skin pigmentation, melanoma and non-melanoma skin cancer and non-invasive imaging are the main areas of interest for Professor del Marmol. In recognition of her work in these fields, she has been awarded several scholarships and grants, including the Major Roche Dermatology Fundamental Research Award. She authored and co-authored more than 116 peer reviewed articles and seven books (H index 36), particularly in Journal of Investigative Dermatology, Experimental Dermatology, Journal of the European Academy of Dermatology and Venereology (JEADV), Nature and New England Journal of Medicine. She is a founding member for the European skin cancer prevention campaign EUROMELANOMA and since 2009 led its European campaign. She is board member of the European Dermatology Forum (EDF), the Academy of Dermatology and Venerology (EADV), the European Academy of Dermato-oncology (EADO) and the European Pigment Cell Society (ESPCR). She is vice-president of the Belgian Society of Dermatology and was elected in 2014 as member of the Belgian Royal Academy of Medicine.
Pierre Hainaut (born 1958, Belgium) is PhD in Biology, University of Liège, Belgium, 1987. After postdocs in France and in the UK (1988–1994), he joined the International Agency for Research on Cancer (IARC, World Health Organization) in 1994, where he held the post of head of Molecular Carcinogenesis from 1999 to 2011. In 2012, he joined the International Prevention Research Institute (iPRI) as Research Director. Since 2014, he has been appointed as Professor of Cancer Biology and Chair of Excellence in Translational Research at Université Grenoble Alpes, France. Since October 2014, he is Director of the Institute of Advanced Biosciences (formerly Institut Albert Bonniot), a multi-thematic research center supported dedicated to epigenetics, chronic diseases and cancer (17 research groups). He is also responsible for Molecular Diagnosis of Cancer at the University Hospital (CHU) of Grenoble, France.
His research focuses on TP53 mutations and on biomarkers of transition from chronic diseases to cancer. From 1994 to 2011, he led the development of the international IARC database of TP53 mutations, a source of information on the causes and consequences of mutations affecting the p53 suppressor protein in cancer. His current research focuses on gain-of-function effects in lung cancer and on biomarkers for early detection of liver and lung cancers, in particular in low-resource countries.
Pierre Hainaut is author of over 400 publications and 50 book chapters (h index: 83, Google Scholar). He has co-edited two books on p53 (25 Years of p53 Research 2005, 2007, p53 in the Clinics, Springer) and a textbook of molecular epidemiology (Molecular Epidemiology: Principle and Practice, IARC Press, 2011).